220386-65-2

UR-3216, a prodrug, is a novel, selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 is the very tight binding of its active metabolite to platelets (Ki for resting platelets is < 1 nM). UR-2992, the active form of UR-3216, binds to platelets for a long period of time, while the unbound drug is rapidly cleared. UR-3216 is a promising, orally active GPIIb/IIIa antagonist for the treatment of cardiovascular diseases.

UR-3216 是一种选择性、具有口服活性的血小板表面糖蛋白 (GPIIb/IIIa) 受体拮抗剂。UR-3216 具有心血管疾病研究的潜力。